|
Getting your Trinity Audio player ready...
|
This morning, many investors will be examining stocks that may have garnered significant attention on Monday, and among them, one stock worth monitoring could be Catheter Precision Inc (NYSE American: VTAK).
Following a significant recent announcement from the company, the stock wrapped up the day with gains of 7.04%, reaching $0.61 per share. Trading at twice its average 30-day volume and closing higher than its 200-day moving average, the stock is entering breakout territory and displaying several bullish indicators. This makes it worth monitoring in the near term.
The U.S.-based medical device firm gained attention in the news cycle yesterday following a significant announcement regarding its LockeT product. The company revealed that the product had been utilized for the first time outside the U.S. at the Heart Hospital of Hamad Medical Corporation in Doha, Qatar.
It’s worth mentioning that the Hamad Medical Corporation serves as Qatar’s primary tertiary and secondary healthcare provider, standing as one of the leading hospital networks in the Middle East. Currently, HMC manages a total of 12 hospitals, comprising 9 specialty hospitals and the remaining 3 being community hospitals.
Dr. Sajad Hayat discussed the LockeT product post-implementation, emphasizing the importance of ease of use and effectiveness in a vascular hemostasis product like LockeT. He affirmed that the product met both criteria. Additionally, Davin Jenkins, the Chief Executive Officer of Catheter Precision, also commented on this milestone.
He observed that aside from the successful debut of the LockeT product beyond the borders of the United States, its value was swiftly acknowledged by the physician. He referenced Dr. Hayat’s observations as a resounding endorsement of the product’s effectiveness.
Related posts:
Ra Medical Systems, Inc. (NYSE American:RMED) is Now Catheter Precision, Inc. (NYSE American: VTAK), Effective Today
US Stocks In The News: VTAK, INBS, KAVL, HALB, SNNC
Catheter Precision (NYSE American: VTAK) Gaining Momentum as VIVO™ Innovative 3D Mapping System is Showcased
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
Catheter Precision Inc (NYSE American: VTAK) Announces Q4 and FY23 Results and Authorizes CEO to Make “Open Market” Purchases of Company Shares